Overview of Alomide

Quick Facts

Property	Description
Active ingredient	Lodoxamide (as Lodoxamide tromethamine)
Form	Ophthalmic solution (eye drops)
Pharmacological class	Mast cell stabilizer, Anti-allergic agent
Common purpose	Prophylactic management of ocular allergy symptoms
Target patient group	Adults and pediatric patients (typically 2 years and older)

Alomide: Composition and Unique Ophthalmic Form

Alomide is a prescription-only medicinal product administered as a sterile, single-ingredient ophthalmic solution (eye drops) for topical ophthalmic use. Its sole active ingredient is the synthetic compound Lodoxamide, delivered in its salt form, Lodoxamide tromethamine. This compound is formulated as an aqueous solution, which facilitates targeted delivery of the therapeutic agent directly to the surface of the eye. This focused topical delivery distinguishes its mechanism of action from anti-allergy medications taken by mouth, which affect the entire body systemically. The formulation is intended for use in adults and pediatric patients generally starting at two years of age.

Pharmacological Class and Preventative Purpose

Lodoxamide is classified as a mast cell stabilizer, a category of anti-allergic agents. The primary function of this drug is prophylactic—to inhibit the biological events that cause allergic symptoms. Lodoxamide works by reducing inflammatory cells in tear fluid after allergen exposure, playing a role in controlling the allergic process. It acts by stabilizing the cell membranes of mast cells within the ocular tissues, thereby preventing the release of inflammatory mediators, such as histamine and leukotrienes. This preventative mechanism is the central purpose of Lodoxamide, helping to manage the underlying cause of ocular irritation rather than only relieving established symptoms.

What side effects are possible with Alomide?

Possible Side Effects and Safety Information

The safety profile for Lodoxamide ophthalmic solution is structured by adverse reactions classified according to their frequency and the body system affected, based on official regulatory documents, such as the U.S. Food and Drug Administration (FDA) prescribing information.

Adverse Reaction Classification

Adverse events are predominantly localized to the eye. The most frequently reported ocular events are transient (short-lived) and occur upon the instillation of the solution, including burning, stinging, or discomfort (observed in approximately 15% of subjects).

Common adverse reactions (occurring in 1% to 5% of subjects) include ocular effects such as pruritus (itching), blurred vision, dry eye, and tearing. Non-ocular events officially listed as common include headache.

Uncommon reactions (occurring in less than 1% of subjects) may involve various system organ classes, including Nervous System Disorders (e.g., dizziness), Gastrointestinal Disorders (e.g., nausea), and other Ocular Disorders (e.g., corneal erosion, eye pain, edema).

Safety Considerations and Restrictions

The medication is contraindicated in patients with known hypersensitivity to Lodoxamide tromethamine or any component of the formulation, which represents the primary serious safety constraint.

Regulatory documents also define specific limitations regarding patient populations and use. Safety and effectiveness have not been established in pediatric patients below the age of two years (FDA). Furthermore, the solution contains benzalkonium chloride, requiring that patients do not wear soft contact lenses during treatment, as the preservative can be absorbed by the lenses.

Overdose and Emergency Response

Overdose Profile and Manifestations

The official regulatory profile differentiates between the exposure routes. No toxic effects are expected following overdose from the intended topical ocular application. Accidental systemic overdose, primarily from oral ingestion, may result in documented transient manifestations.

Reported symptoms following acute ingestion include a sensation of warmth or flushing, profuse sweating (diaphoresis), headache, dizziness, diarrhea, and stomach discomfort. These manifestations, which affect the cardiovascular, nervous, and gastrointestinal systems, are consistent with regulatory labeling.

Systemic Outcomes and Severity

Oral ingestion may lead to transient elevations of systolic and diastolic blood pressure. However, regulatory documents consistently report that no permanent adverse effects were observed following acute, high-dose ingestion scenarios. Treatment is symptomatic and supportive, as no specific antidote is documented in the official labeling.

Mandated Emergency Actions

In the event of accidental ingestion, regulatory sources mandate immediately contacting a health care practitioner, hospital emergency department, or a regional Poison Control Centre. For a topical ocular overdose, the required action is to flush the eye with lukewarm water. Officially described supportive management measures may include considering procedures like gastric lavage or treatment with activated charcoal to decrease further systemic absorption.

Therapeutic Uses of Alomide

What Alomide Treats: Main Uses and Benefits

The medication is used for symptomatic support in defined, chronic allergic inflammatory conditions of the eye, specifically including Vernal Keratoconjunctivitis, Vernal Conjunctivitis, and Vernal Keratitis. It is indicated for conditions characterized by periods of heightened symptoms and may be part of symptomatic management for adult and pediatric patients typically 2 years of age and older.

Alomide is considered relevant for its prophylactic (preventative) therapeutic benefit, playing a role in managing symptoms that may become more disruptive during flare-ups associated with these chronic conditions. This is applied in addressing symptom clusters that may become intense or disruptive, such as pronounced ocular itching (pruritus), noticeable redness, increased tearing, and the challenging foreign body sensation, supporting patients during difficult episodes by easing distress. Clinically, the medication is often summarized by its role in preventative symptomatic support: “It is relevant when supportive symptom management is appropriate, especially to support patients during episodes of heightened discomfort.”

Quick Fact: Relief for Ocular Pruritus and Inflammation The medication is commonly used to help manage the ocular itching associated with chronic allergic disease and contributes to easing the overall symptom load related to inflammatory or irritative states like redness and swelling.

Eligibility and Restrictions for Use

Alomide (lodoxamide tromethamine ophthalmic solution) is intended for topical ophthalmic use and its eligibility profile is defined by official regulatory documentation.

Contraindicated Populations

The medicine is strictly contraindicated and must not be used by individuals with a known hypersensitivity (allergy) to the active ingredient, lodoxamide, or to any other component of the eye drop formulation, including the preservative benzalkonium chloride.

Age-Related Eligibility Rules

Age Group	Regulatory Status
Adults	Approved for use
Children ge 2 Years	Approved for use
Children < 2 Years	Safety and effectiveness have not been established
Older Adults (Geriatric)	No overall differences in safety or effectiveness have been observed when compared to younger patients

Use in Specific Populations

Use during pregnancy (FDA Pregnancy Category B) is only recommended if clearly needed. For nursing mothers, official documentation advises caution as it is unknown whether lodoxamide is excreted into human milk.

Conditional Use Restrictions

Patients who wear soft contact lenses must remove the lenses before instilling the drops due to the presence of benzalkonium chloride, and wait a minimum of 15 minutes before reinsertion.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents for Alomide (Lodoxamide tromethamine ophthalmic solution) establish that the product has a highly limited potential for systemic drug interactions. This is due to the drug's formulation as an ophthalmic solution for topical use, resulting in minimal systemic absorption of the active ingredient.

Systemic Interactions and Contraindications

No known systemic pharmacokinetic or pharmacodynamic drug interactions are documented in the official regulatory labeling, including documents from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Consequently, no specific oral or injectable medicinal products are formally classified as contraindicated due to interaction risk with Lodoxamide in its ophthalmic form.

Administration Timing Restrictions

The only official constraint governing use with other products is a mandatory timing rule for local, topical co-administration:

Other Topical Ophthalmic Products: If more than one topical ophthalmic medicinal product is being used, a timing separation of at least 5 minutes is required between the administration of each product.
Ointment Sequencing: If an eye ointment is among the co-administered products, it must always be administered last.

Interactions with Food, Alcohol, or Supplements

Official regulatory sources do not document any known interactions with food, alcohol, herbal products, or dietary supplements.

Mechanism of Action

Alomide, a mast cell stabilizer, modulates cellular processes at the site of administration, primarily the conjunctival and underlying ocular tissues. The active moiety, lodoxamide, acts on mast cells, which are key effector cells in immediate hypersensitivity. The precise molecular interaction remains under investigation, but the core function is the inhibition of mast cell degranulation.

Mechanistically, lodoxamide is postulated to inhibit calcium influx into the mast cell cytoplasm following antigen challenge. This prevents the rise in intracellular calcium concentration necessary to trigger the fusion of secretory granules with the cell membrane. By stabilizing the mast cell membrane and preventing this exocytosis, lodoxamide limits the release of preformed and newly synthesized inflammatory mediators.

Downstream consequences include a reduction in the release of key signaling molecules, such as histamine, slow-reacting substances of anaphylaxis (peptido-leukotrienes), and various chemotactic factors. The drug also exhibits an inhibition of eosinophil chemotaxis, thereby reducing the recruitment of these inflammatory cells to the tissue. The system-level physiological consequence of this dual-action modulation is the dampening of the Type I immediate hypersensitivity reaction and the associated inhibition of increased cutaneous vascular permeability.

Dosage and Administration Information

How Alomide is Used: Administration Guidelines

Alomide (lodoxamide tromethamine ophthalmic solution 0.1%) is a prescription medicine with usage instructions established for the management of chronic allergic inflammatory conditions of the eye.

Administration Scope

Feature	Guideline
Route of Administration	Topical ophthalmic use only; applied directly to the surface of the eye.
Dosing Schedule	One to two drops administered to the affected eye(s) four times per day (QID).
Age-Group Rules	Approved for use in adults and pediatric patients 2 years of age and older.
Missed-Dose Rules	If a dose is missed, administer it as soon as remembered. If close to the next scheduled dose, skip the missed dose and resume the regular schedule.

Administration Context and Procedure

Lodoxamide is intended for continuous, prophylactic use over a defined period, which may be up to three months, as directed by a healthcare professional. Regular application four times daily is necessary to maintain the consistent effect required for its use pattern.

Procedural Constraints:

Contact Lenses: Soft contact lenses must be removed prior to administration. Patients should wait a specified time, typically 15 minutes, before reinserting soft contact lenses.
Contamination Control: The tip of the dropper must not be touched to the eye, eyelid, or any surface during the application process to avoid contamination of the sterile solution.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has investigated whether this combination may influence patient outcomes, including the duration of painful inflammation. This section provides an overview of the key clinical and non-clinical studies that have explored the use and research of this compound.

Studies on Compound Activity

Key research has explored the compound's activity on an inflammatory pathway in the synovium. Studies examined whether the observations regarding the mechanism corresponded to changes in reported joint pain.

In-vitro models: Studies focused on the compound's specific interaction with the target receptor complex. Research detailed the compound's specific interaction with the target receptor complex.
Animal studies: Non-clinical research has primarily examined the compound's biodistribution and elimination profile. These studies utilized varying dosages, with some research focusing on lower doses.

Clinical Trial Summary

Research has explored whether the drug is associated with changes in chronic pain, examining the timing of potential relief after administration. Clinical trials documented whether the administration schedule used was consistent across study participants when assessing outcomes. Clinical trials documented adverse event profiles across the adult patient population studied.

Phase III RCTs: Efficacy Assessment

The pivotal Phase III trials (N=1,200 participants) compared the combination therapy to a placebo control group over a 52-week period.

Flare-up frequency: This trial reported that participants receiving the drug experienced a numerically lower average flare-up frequency compared to the control group, noting a 35% difference in means.
Pain scores: Changes in the Visual Analog Scale (VAS) pain scores were measured weekly. The analysis reported that the treatment group showed a difference in the median change in VAS score compared to the control group at the primary endpoint (week 24).

Phase II Studies: Dose Ranging and Safety

Early-stage research focused on identifying the appropriate dose range and further characterizing the safety profile. Studies investigated whether combined therapy was associated with changes in long-term mobility, reporting a notable difference from the control group. The data provides insight into the drug's performance in severe cases, with continued research needed to understand the full clinical context.

Key Studies & References

Dose Ranging and Long-Term Mobility Outcomes of Alomide in Severe Cases: A Phase 2 Clinical Study

Frequently Asked Questions (FAQ)

Common questions about Alomide (FAQ)

Q: Is Alomide the same type of medicine as Pataday?

Official information classifies Alomide as a mast cell stabilizer. This means it works by stabilizing certain cells in the eye to prevent them from releasing inflammatory chemicals, such as histamine. Other allergy eye drops, like Pataday, may be classified differently or use a dual mechanism of action.

Q: How quickly do the effects of Alomide usually start?

Alomide is a prophylactic treatment, meaning it is intended to prevent symptoms before they start, and consistent administration is necessary. For this reason, the full effect of the medicine takes time to build up. While some symptom improvement may be noticed within a few days, official documents indicate it can take up to four weeks to reach its maximum therapeutic effect.

Q: Why are people talking about using Alomide for general eye redness?

Official sources indicate that Alomide is used to treat the symptoms associated with allergic eye disorders. Since inflammation from these allergies often causes eye redness (hyperemia), modulating the allergic reaction is associated with a reduction in these and other symptoms like itching and burning. The drug's mechanism is intended to prevent the underlying cellular reaction associated with these symptoms.

Q: What is the difference between Alomide and an antihistamine eye drop?

Alomide is classified as a mast cell stabilizer. Its function is to prevent cells in the eye from releasing inflammatory substances, including histamine. This is a different mode of action than an antihistamine, which works by blocking the effects of histamine that has already been released into the body.

Q: What type of allergy symptoms is Alomide generally used for?

The medicine is indicated for the treatment of specific allergic eye conditions, such as vernal keratoconjunctivitis and vernal keratitis. The signs and symptoms associated with these conditions, like itching, burning, redness, and swelling, are the conditions for which the medication is indicated.

Q: What is the expected duration of treatment with Alomide?

The duration of treatment is determined by a healthcare provider and is typically related to the period during which the patient is exposed to allergens. Official documents define the use period as continuous, prophylactic use for a defined time, generally up to three months. The intended effect of the medicine relies on consistent, regular administration.

Q: Are there any known severe or rare side effects of Alomide?

Official documentation classifies adverse reactions by their frequency. Rare adverse reactions, which occur in a very small percentage of subjects, may involve issues like eye pain, corneal erosion (damage to the surface of the eye), or eyelid swelling. A primary safety constraint noted in official documents is a known allergy to the active ingredient or other components of the eye drop.

Q: Are there any restrictions on who can use Alomide based on other health conditions?

The medicine is documented as being strictly contraindicated in individuals with a known allergy to lodoxamide tromethamine or any other ingredient in the eye drop formulation. Regulatory documents do not provide specific warnings based on conditions like kidney or liver impairment, and dose adjustments are not recommended for these organ systems.

Q: Does Alomide help with eye watering or discharge?

Yes, official documents indicate that Alomide is used to treat the symptoms of eye allergies. These symptoms include common allergic responses such as increased tearing (lacrimation) and eye discharge. The medicine works by modulating the allergic process, which is associated with these symptoms.

Q: Can Alomide be used for year-round allergy symptoms?

The medicine is indicated for specific allergic eye disorders which can be recurrent or chronic in nature. Its use is defined as continuous and prophylactic over a defined period, which official sources state is generally up to three months. This consistent use supports the management of the underlying allergic inflammation.

Q: Are there any specific activities or environments I should avoid while using Alomide?

Regulatory information notes that if temporary blurred vision occurs immediately following instillation of the eye drops, official information advises waiting until the vision clears before driving or operating machinery. Aside from this potential temporary effect, no other specific restrictions on environments or activities are documented in official product information.

Q: Does Alomide cause drowsiness or affect my ability to drive?

Official product information notes that blurred vision is a common, temporary side effect upon instillation, and this potential effect may impair the ability to drive until vision is clear. Less common or rare adverse reactions that have been reported include dizziness or somnolence (drowsiness).

Q: Does Alomide contain any steroids?

The active ingredient in this eye drop solution is Lodoxamide tromethamine. It is classified as a mast cell stabilizer, which is a type of anti-allergic agent. Official documentation confirms that the medicine is not classified as a topical steroid.

Q: Are there generic versions of Alomide available?

Official records from the U.S. Food and Drug Administration (FDA) indicate that generic equivalents for the 0.1% ophthalmic solution of Lodoxamide tromethamine are currently approved and available for substitution. The availability of generic alternatives is subject to the regulatory review of specific formulations.

Q: What should I do if I accidentally put too many drops of Alomide in my eye?

In the event of an accidental topical overdose, official regulatory recommendations advise that the product should be flushed from the eye. The rinsing is advised to be done using lukewarm water to help remove any excess solution from the eye's surface.

Q: Is Alomide a relatively new drug, or has it been around for a while?

The active ingredient in this medicine, Lodoxamide tromethamine, has been available for a significant period. The U.S. Food and Drug Administration (FDA) first approved this compound for ophthalmic use in the year 1993.

Q: Is Alomide safe for people with high blood pressure?

Because the medicine is a topical eye solution, systemic absorption of the active ingredient is minimal. Regulatory documentation only notes effects on blood pressure following massive oral ingestion, which resulted in temporary, transient elevations.

How should Alomide be stored and disposed of?

How to Store and Dispose of Alomide (Lodoxamide Tromethamine)

Storage Requirements

Alomide ophthalmic solution must be stored at controlled room temperature, specifically between 15 C and 27 C (59 F and 80 F). It is mandatory to keep the medicine from freezing and to store the bottle upright and tightly closed. The dropper tip must not be touched to any surface to maintain sterility. As a critical safety rule, the medication must be stored out of the sight and reach of children.

Stability and Disposal

To ensure efficacy and sterility, the container's contents must be discarded one month (four weeks) after the bottle is first opened. Unused or expired Alomide should not be disposed of in household trash or via wastewater. Regulatory guidance requires that these medicines be disposed of using a local drug take-back program or by mixing the product with an undesirable substance before discarding in the trash.

Alomide